Evidence map›Paper›PMID 36077697›Full record

ArticleCancers2022

DNMT3A/

Jiheng Xu, Rui Yang, Jingxia Li, Lidong Wang, Mitchell Cohen, Diane M Simeone, Max Costa, Xue-Ru Wu

Open access · goldAbstract read
In one paragraph

Article in Cancers, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 8 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 2 institutions in 1 country.

Jiheng XuDepartment of Medicine, New York University School of Medicine, New York, NY 10016, USA.ORCID 0000-0002-3538-3174
Rui YangDepartment of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Jingxia LiDepartment of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Lidong WangDepartment of Surgery, New York University School of Medicine, New York, NY 10016, USA.
Mitchell CohenDepartment of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Diane M SimeoneDepartment of Surgery, New York University School of Medicine, New York, NY 10016, USA.
Max CostaDepartment of Medicine, New York University School of Medicine, New York, NY 10016, USA.
Xue-Ru WuDepartment of Pathology, New York University School of Medicine, New York, NY 10016, USA.ORCID 0000-0001-6058-6291
New York University · USVA NY Harbor Healthcare System · US

Funding

Reagent/Service CoreP01CA165980 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI WU, XUE-RU · 2013 to 2023
$13.5M
SESN2 and therapeutic effect of Isohapontigenin (ISO)R01CA217923 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI COSTA, MAX, SUN, HONG · 2018 to 2022
$2.1M
BLRD VA I01 BX002049BLRD VA I01 BX005602BLRD VA IK6 BX004479NCI NIH HHS 5P01CA165980NCI NIH HHS P01 CA165980NCI NIH HHS R01 CA217923
6 · The paper itself

Abstract

The stem-cell-like behavior of cancer cells plays a central role in tumor heterogeneity and invasion and correlates closely with drug resistance and unfavorable clinical outcomes. However, the molecular underpinnings of cancer cell stemness remain incompletely defined. Here, we show that

Indexed as

DNMT3Amuscle-invasiveRac1SNHG1stemnessurothelial carcinoma

Identifiers

PMID36077697
PMCPMC9454896
OpenAlexW4293659621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.